This review concluded that the generally poor evidence indicated that magnetic resonance imaging should be the firstline investigation for the identification of acoustic neuroma (benign cranial nerve tumours) in appropriately selected patients. Although the authors' conclusions appeared to reflect the evidence available, given limitations with the included studies and the reporting in the review, they should be interpreted with caution.
Study selection
Studies comparing an investigative test with magnetic resonance imaging (MRI, reference test) in patients, over the age of 16 (or studies with only a small number of patients under the age of 16), with unilateral sensorineural hearing impairment, asymmetric sensorineural hearing impairment, or unilateral tinnitus, were eligible for inclusion. Eligible studies were required to report sensitivity/specificity of the diagnostic test, or present data from which these could be calculated. Studies published before 1990 were excluded, as were studies in which patients with neurofibromatosis type 2 could not be excluded.
The majority of included studies were conducted in the USA. Where reported, ages ranged between 13 and 87. Tumour sizes varied considerably. Studies either compared the use of auditory brain-stem response with MRI, or compared highresolution imaging without gadolinium (T2W or T2*W properties) versus gadolinium-enhanced imaging (gold standard GdT1W sequence). Some studies comparing auditory brain-stem response with MRI also reported the use of radiology, surgery or computerised tomography (CT)/MRI as comparators. Auditory brain-stem response criteria for hearing abnormality varied between studies. Some individual studies reported other outcomes, including positive predictive value (PPV), negative predictive values (NPV) inter-aural difference of wave V latencies, and inter-peak latency.
The authors stated that clinical and methodological experts selected papers for review, but no further details were provided.
Assessment of study quality
Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool.
The authors did not state how may reviewers performed the validity assessment.
Data extraction
The number of patients/ears identified, with or without acoustic neuroma, with MRI or other investigative tests (i.e. true positives, true negatives, false positives and false negatives), and sensitivities and specificities, were extracted into a 2x2 table. Where sensitivity and specificity were not reported, these were calculated from the data available, along with their 95% confidence intervals (CIs). The authors did not state how many reviewers extracted the data.
Methods of synthesis
A random-effects model was used to pool sensitivities and specificities according to the comparative investigative test (i.e. auditory brain-stem response or alternative MRI). Statistical heterogeneity was assessed using the X 2 and I 2 statistics. Sensitivity analyses were conducted according to the categories of acoustic neuroma size (up to 1.0 cm, 1.0 to 2.0cms, and above 2.0cms) in studies comparing auditory brain-stem response versus MRI.
Results of the review
Twenty seven studies were included in the review. Sample sizes ranged from 20 to 1,233 participants. Most of the studies were retrospective. One study comparing auditory brain-stem response with magnetic resonance imaging (MRI) comparison, and three studies comparing MRI were not included in the pooled synthesis; the reasons for this were unclear. The quality of studies using auditory brain-stem response as the comparator ranged between 5 and 11, with only one study scoring greater than 10. Studies comparing MRI reported quality scores ranging between 9 and 13, with most scoring more than 10.
Auditory brain-stem response versus MRI (16 studies, n=2,649 patients): Auditory brain-stem response showed high sensitivity (identified a higher rate of true positives) compared with MRI, with a pooled sensitivity of 0.85 (95% CI 0.82 to 0.87; 15 studies). Sensitivity analyses indicated that sensitivity was dependent on the size of the tumour, with high levels of sensitivity using auditory brain-stem response reported in patients with tumours larger than 1cm and not in patients with smaller tumours. Only three studies reported specificity, which was also high for auditory brain-stem response compared with MRI (identified a higher rate of true negatives), with a pooled specificity of 0.77 (95% CI: 0.73 to 0.81).
There was significant statistical heterogeneity among studies reporting sensitivity (p<0.0001; I 2 =88%) and specificity (p<0.001; I 2 =86%). Sensitivity analyses significantly reduced statistical heterogeneity, which was no longer significant for each category of tumour size.
High-resolution imaging without gadolinium versus gadolinium-enhanced imaging (11 studies, n=2,572 patients): Highresolution imaging without gadolinium (T2W or T2*W properties) had high sensitivity (good test accuracy) compared with the gold standard gadolinium-enhanced imaging (GdT1W sequence) MRI: T2W sensitivity was 98% (95% CI 94 to 99; five studies); T2*W sensitivity was 96% (95% CI 86 to 99; three studies -98%, 95% CI 95 to 99% according to forest plot). The pooled specificity for T2W was 96% (95% CI 94 to 96; five studies) and for T2*W 97% (95% CI 95 to 98; three studies). There was evidence of statistical heterogeneity among studies reporting specificity (T2W I 2 =87.8% and T2*W I 2 =92.8%).
Cost information
A separate systematic review was undertaken in the section to evaluate cost-effectiveness.
